Sagent Pharmaceuticals Issues Nationwide Recall

News
Article

The company is voluntarily recalling one lot of Oxacillin for Injection, USP, 10 g.

On August 18, 2016, Sagent Pharmaceuticals voluntarily recalled one lot of Oxacillin for Injection, USP, 10 g nationwide due to particulate matter. The recall was in response to a complaint about a single vial containing small, dark particulate matter. The particulate was found in the solution after reconstitution and has been identified iron oxide. Sagent has not received notice of any adverse events associated with the lot.

The recalled product was manufactured by Astral SteriTech Private Limited and distributed by Sagent nationwide from June–July 2016. The product is packaged in cartons containing 10 x 10 gram Pharmacy Bulk Package bottles identified by NDC 25021-163-99. The lot number being recalled is Lot OXT512 (Exp. Date March 2017).

According to Sagent, Oxacillin for Injection, USP, 10 g is available by prescription only for the treatment of infections caused by penicillinase producing staphylococci that have demonstrated susceptibility to the drug. A metal particulate in an injectable product may result in local swelling, irritation of blood vessels or tissue, or blockage of blood vessels.

Sagent is advising customers to quarantine and discontinue distribution of the product. Adverse events may be reported to FDA.

Source: FDA

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.